X4 Pharmaceuticals, Inc.
XFOR
$0.19
$0.00281.50%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 62.98% | 84.92% | 113.52% | -34.39% | -7.78% |
| Total Depreciation and Amortization | 89.98% | 21.62% | -15.77% | -30.18% | -18.32% |
| Total Amortization of Deferred Charges | -7.86% | -4.55% | -0.73% | 1.38% | 1.20% |
| Total Other Non-Cash Items | -3,399.97% | -1,097.31% | -478.07% | 400.47% | -69.13% |
| Change in Net Operating Assets | 677.62% | -134.71% | -82.42% | -72.67% | -94.00% |
| Cash from Operations | -35.63% | -43.02% | -30.25% | -24.24% | -25.17% |
| Capital Expenditure | -443.33% | -442.37% | -293.33% | -22.22% | 41.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -154.23% | -238.17% | -376.09% | -- | -- |
| Cash from Investing | 550.11% | 801.88% | 1,752.15% | -22,340.00% | -14,349.51% |
| Total Debt Issued | -11.11% | -11.11% | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 41.23% | 41.23% | -159.62% |
| Issuance of Common Stock | -99.57% | -99.80% | -99.86% | -41.02% | -43.85% |
| Repurchase of Common Stock | -- | -- | -- | -1,177.27% | -726.47% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 94.73% | 103.50% | 86.86% |
| Cash from Financing | -77.07% | -86.41% | -76.94% | -17.71% | -24.49% |
| Foreign Exchange rate Adjustments | -257.58% | -35.82% | -110.48% | -171.43% | 194.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -92.16% | -166.86% | -88.13% | -224.26% | -157.06% |